As a direct result of CBV’s support, Block Biosciences successfully achieved two key milestones in our development plan… These milestones significantly de-risked our development pathway and strengthened our overall commercialization readiness.
BLOCK Biosciences (Amie Phinney, CEO)CBV’s support was instrumental in helping Copoly.ai build a strong intellectual property foundation at a critical early stage. Through a combination of targeted funding and practical IP expertise, CBV enabled us to define a clear, defensible IP strategy aligned with our product roadmap and long-term commercialization goals.
Copoly.ai (Peng Zhang, CEO)CBV helped us negotiate a couple of crucial partnerships, including one with a local hospital for patient samples and pre-clinical trials. We can’t thank CBV enough for their incredible, strategic support and would recommend them to anyone as excellent enablers of Canada’s future in life sciences.
Hylid Diagnostics (Jack Fairbank, CEO)